Joel Claiborne Stephens
Career history of Joel Claiborne Stephens
Former positions of Joel Claiborne Stephens
| Companies | Position | Start | End |
|---|---|---|---|
The Genetics Co., Inc.
 The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Corporate Officer/Principal | - | - |
| NCI INC | Corporate Officer/Principal | - | - |
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Corporate Officer/Principal | - | - |
| National Institute of Health Policy | Corporate Officer/Principal | - | - |
Motif BioSciences, Inc.
 Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - | - |
Statistics
International
| United States | 5 |
| Switzerland | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 3 |
| Technology Services | 2 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 5 |
|---|---|
Motif BioSciences, Inc.
Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY. | Health Technology |
Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
| National Institute of Health Policy | |
Empower AI, Inc.
 Empower AI, Inc. Information Technology ServicesTechnology Services Empower AI, Inc. engages in the provision of commercial artificial intelligence (AI) technology solutions defense, intelligence, health, and civilian government agencies. It offers advanced analytics and data science, engineering and logistics, information technology (IT) sustainment and modernization, IT service management, and AI solutions. The company was founded in 1989 and is headquartered in Reston, VA. | Technology Services |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Health Services |
